Mark Lynch

20.2k citations
91 papers · 8.0k · 4 hit papers · h-index 30

Impact in

  • Hepatology top 0.5%
    • Hepatocellular Carcinoma Treatment and Prognosis
  • Oncology top 1%
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers

Papers in

    • TGF-β signaling in diseases 5
    • Single-cell and spatial transcriptomics 4
    • Angiogenesis and VEGF in Cancer 4
    • Cancer Immunotherapy and Biomarkers 14
    • Cancer Cells and Metastasis 4

Mark Lynch

91 papers receiving 7.8k citations

Mark Lynch's Hit Papers

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity 2010 · 1.1k citations
1.1k0+6+13Years since publication50010001.5k

Peers

Mark Lynch
Comparison fields: 5 of 154
  • Hepatology 1.3k
  • Oncology 2.2k
  • Cancer Research 897
  • Hematology 596
  • Pathology and Forensic Medicine 911
Replace Bert H. O’Neil with:
Bert H. O’Neil United States
Charles Erlichman United States
Ross C. Donehower United States
David Khayat France
Scott Wadler United States
Limin Zheng China
Jean L. Grem United States
Sandrine Faivre France
Chris H. Takimoto United States
H. Cortés-Funes Spain
Mark Lynch relative to Bert H. O’Neil United States Bert H. O’Neil's profile →
Citations per field
00.5×1.5×2.2×
Bert H. O’Neil · 1×
Citations per year

Countries citing papers authored by Mark Lynch

Since Specialization
Citations

This map shows the geographic impact of Mark Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lynch more than expected).

Fields of papers citing papers by Mark Lynch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lynch. The network helps show where Mark Lynch may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Lynch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Lynch Line = papers co-authored together Mark Lynch links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Hit paper breakdown →
20061507
2
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Hit paper breakdown →
20061307
3
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Hit paper breakdown →
20081194
4
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Hit paper breakdown →
20101066
5 2006397
6 2016187
7 1988161
8 2011160
9 2007136
10 2020136
11 2019118
12
Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
200196
13 200377
14 201774
15 201971
16 199565
17 201563
18 199163
19 199160
20
Youth Justice: Criminal Trajectories
200346

About Mark Lynch

Mark Lynch is a scholar working on Molecular Biology, Oncology, Surgery, Otorhinolaryngology and Hematology, having authored 91 papers that have together received 8.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (14 papers), Head and Neck Cancer Studies (10 papers), Multiple Myeloma Research and Treatments (7 papers), Clostridium difficile and Clostridium perfringens research (6 papers), TGF-β signaling in diseases (5 papers), Single-cell and spatial transcriptomics (4 papers), Cancer Cells and Metastasis (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). The work is most often cited by research in Hepatology (1.3k citations), Oncology (2.2k citations), Cancer Research (897 citations), Hematology (596 citations) and Pathology and Forensic Medicine (911 citations). Mark Lynch has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Scott M. Wilhelm, Lila Adnane, Jacques Dumas, Augusto Villanueva, Josep M. Llovet, Philippa Newell, Dean Wilkie, Charles Chen, Ronit Simantov and Timothy B. Lowinger. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Blood, Molecular Cancer Therapeutics and The Science of The Total Environment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact